Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors

Clinical Sarcoma Research

Enrique de Álava⁸  Carmen Balañá⁷  Rafael Ramos⁶  Luis Gonçalves⁴  Jaume Ordi⁵  Javier Saenz de Santamaría²  Nieves Hernández^1,10  Aurora Astudillo^1,11  Maria Carmén Gómez⁹  August Vidal^1,12  Francesc Tresserra³  Susana Fraile⁸  Teresa Hernández⁸  Ruth Sardinha¹ 

[1] Pathology Department, Hospital Espírito Santo E.P.E, Évora, Portugal;Pathology Department, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain;Pathology Department, USP-Institut Universitari Dexeus, Barcelona, Spain;Pathology Department, Hospital do Espírito Santo E.P.E, Évora, Portugal;Pathology Department, Hospital Clinic de Barcelona, Barcelona, Spain;Pathology Department, Hospital Son Espases, Palma de Mallorca, Spain;Medical Oncology Service, Catalan Institute of Oncology - Hospital Germans Trias i Pujol, Badalona, Spain;Centro de Investigación del Cáncer-IBMCC USAL-CSIC, Salamanca, Spain;Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;Anatomical Pathology Department, Hospital Universitario de la Laguna, Canarias, Spain;Pathology Department, Hospital Universitario Central de Asturias, Oviedo, Spain;Pathology Department, Hospital de Bellvitge, Barcelona, Spain

关键词: Systemic treatment;    EGFR;    PDGFRA;    KIT;    Tyrosine kinase inhibitors;    Endometrial stromal tumors;   

Others  :  861493
DOI  :  10.1186/2045-3329-3-3

 received in 2012-12-13, accepted in 2013-03-04,  发布年份 2013

【 摘 要 】

Background

The systemic treatment of malignant endometrial stromal tumors (EST) is not well established. A few reports describe objective responses to imatinib, which suggest a novel therapeutic strategy for these tumors. Due to these facts, we aimed to perform a retrospective analysis of possible molecular targets of tyrosine kinase inhibitors (TKI) in EST: KIT, PDGFRA and EGFR.

Methods

52 endometrial stromal sarcomas and 13 undifferentiated endometrial sarcomas were examined and reviewed. Mutational analysis were performed for exons 9, 11, 13, and 17 of the KIT gene, exons 12 and 18 of the PDGFRA gene and exons 18, 19, 20 and 21 of the EGFR gene. The incidence and distribution of the KIT, PDGFRA, and EGFR expression were examined by immunohistochemistry, and EGFR amplification was assessed by fluorescence in situ hybridization.

Results

No mutations in KIT, PDGFRA and EGFR genes were detected. Overexpression of KIT, PDGFRA, EGFR, was detected in 2 (3%), 23 (35.4%), 7 (10.8%) cases respectively, whereas amplification of EGFR gene was not found.

Conclusions

Absence of significant expression, amplification and activating mutations on these tyrosine kinase receptors suggest that it is unlikely that EST can benefit from therapies such as TKI on the systemic setting.

【 授权许可】

   
2013 Sardinha et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A: Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol 2008, 111:74-81.
• [2]WHO: Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
• [3]Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK: Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol 2008, 108:306-11.
• [4]Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Lossl K, Schleicher U: Outcome and prognostic factors in endometrial stromal tumors: a rare cancer network study. Int J Radiat Oncol Biol Phys 2012, 82:e757-63.
• [5]Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB: Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009, 54:355-64.
• [6]Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Trope CG: The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996, 62:254-9.
• [7]Prat J: FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009, 104:177-8.
• [8]Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, Kapp DS: Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008, 99:1210-5.
• [9]Toki T, Shimizu M, Takagi Y, Ashida T, Konishi I: CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2002, 21:41-7.
• [10]Chu PG, Arber DA, Weiss LM, Chang KL: Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001, 14:465-71.
• [11]Reich O, Regauer S, Urdl W, Lahousen M, Winter R: Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 2000, 82:1030-4.
• [12]Reich O, Regauer S: Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol 2004, 17:104-8.
• [13]Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, Cass I: Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009, 115:466-71.
• [14]D’Angelo E, Spagnoli LG, Prat J: Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009, 40:1571-85.
• [15]Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M: Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 2008, 32:1228-38.
• [16]Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, Dal Cin P, Fletcher JA, Sklar J: Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 2001, 98:6348-53.
• [17]Micci F, Panagopoulos I, Bjerkehagen B, Heim S: Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 2006, 66:107-12.
• [18]Panagopoulos I, Mertens F, Griffin CA: An endometrial stromal sarcoma cell line with the JAZF1/PHF1 chimera. Cancer Genet Cytogenet 2008, 185:74-7.
• [19]Panagopoulos I, Micci F, Thorsen J, Gorunova L, Eibak AM, Bjerkehagen B, Davidson B, Heim S: Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One 2012, 7:e39354.
• [20]Gil-Benso R, Lopez-Gines C, Navarro S, Carda C, Llombart-Bosch A: Endometrial stromal sarcomas: immunohistochemical, electron microscopical and cytogenetic findings in two cases. Virchows Arch 1999, 434:307-14.
• [21]Halbwedl I, Ullmann R, Kremser ML, Man YG, Isadi-Moud N, Lax S, Denk H, Popper HH, Tavassoli FA, Moinfar F: Chromosomal alterations in low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization. Gynecol Oncol 2005, 97:582-7.
• [22]Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA: 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA 2012, 109:929-34.
• [23]Kurihara S, Oda Y, Ohishi Y, Kaneki E, Kobayashi H, Wake N, Tsuneyoshi M: Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Mod Pathol 2010, 23:225-34.
• [24]Lee CH, Ali RH, Rouzbahman M, Marino-Enriquez A, Zhu M, Guo X, Brunner AL, Chiang S, Leung S, Nelnyk N: Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma with YWHAE-FAM22 Rearrangement. Am J Surg Pathol 2012, 36:1562-70.
• [25]Lee CH, Marino-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, Amant F, Gilks CB, van de Rijn M, Oliva E: The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012, 36:641-53.
• [26]Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O’Meara AT, Amezcua CA: The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003, 90:402-6.
• [27]Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, Ueland FR, van Nagell JR, Ahmed MM, Lele SM: Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 2003, 91:9-14.
• [28]Klein WM, Kurman RJ: Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003, 22:181-4.
• [29]Leath CA 3rd, Straughn JM Jr, Conner MG, Barnes MN 3rd, Alvarez RD, Partridge EE, Huh WK: Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med 2004, 49:71-5.
• [30]Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente MP: Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol 2004, 95:632-6.
• [31]Zafrakas M, Theodoridis TD, Zepiridis L, Venizelos ID, Agorastos T, Bontis J: KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature. Eur J Gynaecol Oncol 2008, 29:264-6.
• [32]Martin J, Ramesh A, Kuruvilla S, Lalitha D: Uterine C-Kit positive low grade stromal sarcoma. Indian J Med Paediatr Oncol 2009, 30:113-5.
• [33]Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A: Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumour Biol 2011, 32:451-9.
• [34]Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ: Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 2011, 121:323-7.
• [35]Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, Ramondetta LM: Imatinib mesylate (gleevec)–targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 2005, 13:167-70.
• [36]Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balana C: A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol 2006, 101:545-7.
• [37]Trojan A, Montemurro M, Kamel M, Kristiansen G: Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. Ann Oncol 2009, 20:1898-9.
• [38]Liegl B, Gully C, Reich O, Nogales FF, Beham A, Regauer S: Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology 2007, 50:448-52.
• [39]Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD: PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol 2007, 104:524-8.
• [40]Moinfar F, Gogg-Kamerer M, Sommersacher A, Regitnig P, Man YG, Zatloukal K, Denk H, Tavassoli FA: Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J Surg Pathol 2005, 29:485-9.
• [41]Murray S, Linardou H, Mountzios G, Manoloukos M, Markaki S, Eleutherakis-Papaiakovou E, Dimopoulos MA, Papadimitriou CA: Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res 2010, 686:68-73.
• [42]Mitsuhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, Ban S, Ogawa F, Hirose T, Ishihara O, Shimizu M: KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol 2007, 11:49-54.
• [43]Kalender ME, Sevinc A, Yilmaz M, Ozsarac C, Camci C: Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18 F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol 2009, 63:555-9.
• [44]Parsons M, Grabsch H: How to make tissue microarrays. Diagn Histopathol 2009, 15:142-50.
• [45]Agoff SN, Grieco VS, Garcia R, Gown AM: Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol 2001, 9:164-9.
• [46]Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ: Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol 2004, 92:71-9.
• [47]de Alava E, Ocana A, Abad M, Montero JC, Esparis-Ogando A, Rodriguez CA, Otero AP, Hernandez T, Cruz JJ, Pandiella A: Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007, 25:2656-63.
• [48]Corless CL, McGreevey L, Haley A, Town A, Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160:1567-72.
• [49]Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000, 157:1091-5.
• [50]Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-10.
• [51]Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-500.
• [52]Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-37.
• [53]van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007, 18:99-103.
• [54]Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH: EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009, 24:48-54.
• [55]Varella-Garcia M: Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006, 1:19. BioMed Central Full Text
• [56]Tanner EJ, Garg K, Leitao MM Jr, Soslow R, Hensley ML: High grade undifferentiated uterine sarcoma: Surgery, treatment, and survival outcomes. Gynecol Oncol 2012, 127:27-31.
• [57]Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dorken B, Reichardt P: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006, 101:464-9.
• [58]Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C: Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 2001, 82:384-8.
• [59]Sylvestre VT, Dunton CJ: Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. Horm Cancer 2010, 1:112-5.
• [60]Spano JP, Soria JC, Kambouchner M, Piperno-Neuman S, Morin F, Morere JF, Martin A, Breau JL: Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 2003, 20:87-93.
• [61]Leunen M, Breugelmans M, De Sutter P, Bourgain C, Amy JJ: Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 2004, 95:769-71.
• [62]Altman AD, Nelson GS, Chu P, Nation J, Ghatage P: Uterine sarcoma and aromatase inhibitors: tom baker cancer centre experience and review of the literature. Int J Gynecol Cancer 2012, 22:1006-12.
• [63]Leiser AL, Hamid AM, Blanchard R: Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Gynecol Oncol 2004, 94:567-71.
• [64]Krauss K, Bachmann C, Hartmann JT, Siegmann K, Sotlar K, Wallwiener D, Huober J: Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. Anticancer Res 2007, 27:3477-80.
• [65]Klaritsch P, Reich O, Regauer S, Bauernhofer T: Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem-cell support: A case report. Eur J Gynaecol Oncol 2006, 27:297-8.
• [66]Leyvraz S, Zweifel M, Jundt G, Lissoni A, Cerny T, Sessa C, Fey M, Dietrich D, Honegger HP: Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 2006, 17:646-51.
• [67]Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N: Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the gynecologic oncology group. Obstet Gynecol 1996, 87:747-50.
• [68]Yamawaki T, Shimizu Y, Hasumi K: Treatment of stage IV “high-grade” endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. Gynecol Oncol 1997, 64:265-9.
• [69]Numa F, Umayahara K, Ogata H, Nawata S, Sakaguchi Y, Emoto T, Kawasaki K, Hirakawa H, Sase M, Oga A, Kato H: De novo uterine sarcoma with good response to neo-adjuvant chemotherapy. Int J Gynecol Cancer 2003, 13:364-7.
• [70]Szlosarek PW, Lofts FJ, Pettengell R, Carter P, Young M, Harmer C: Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel. Anticancer Drugs 2000, 11:275-8.
• [71]Valduvieco I, Rovirosa A, Colomo L, De San Juan A, Pahisa J, Biete A: Endometrial stromal sarcoma. Is there a place for radiotherapy? Clin Transl Oncol 2010, 12:226-30.
• [72]Weitmann HD, Knocke TH, Kucera H, Potter R: Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 2001, 49:739-48.
• [73]Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A: Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996, 63:247-53.
• [74]Ferrer F, Sabater S, Farrus B, Guedea F, Rovirosa A, Anglada L, Delannes M, Marin S, DuBois JB, Daly-Schveitzer N: Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the grup oncologic catala-occita. Int J Radiat Oncol Biol Phys 1999, 44:47-52.
• [75]Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G: Prevalence of KIT expression in human tumors. J Clin Oncol 2004, 22:4514-22.
• [76]Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O, Shimizu M: Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol 2006, 25:70-6.
• [77]Cossu-Rocca P, Contini M, Uras MG, Muroni MR, Pili F, Carru C, Bosincu L, Massarelli G, Nogales FF, De Miglio MR: Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis. Int J Gynecol Pathol 2012, 31:570-579.
• [78]Park JY, Kim KR, Nam JH: Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma. Int J Gynecol Cancer 2013, 23:81-9.
• [79]Oliva E, Young RH, Amin MB, Clement PB: An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002, 26:403-12.
• [80]Hornick JL, Fletcher CD: Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002, 117:188-93.
• [81]Winter WE 3rd, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, Birrer MJ: Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003, 91:3-8.
• [82]Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994, 54:3049-53.
• [83]Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52:3213-9.
• [84]Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Hyung WJ, Noh SH, Kim JH, Yun CO, Liu ET: Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005, 24:1066-74.
• [85]Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K: Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005, 4:1270-4.
• [86]Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC: Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. J Clin Oncol 2008, 26:3418-25.
• [87]Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005, 103:2128-31.
• [88]Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O’Malley DM, Birrer MJ: Efficacy and safety of imatinib mesylate (gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a gynecologic oncology group phase Il trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010, 117:248-54.
• [89]Serrano C, Mackintosh C, Herrero D, Martins AS, de Alava E, Hernandez T, Perez-Fontan J, Abad M, Perez A, Serrano E: Imatinib is not a potential alternative treatment for uterine leiomyosarcoma. Clin Cancer Res 2005, 11:4977-9. author reply 79–80
• [90]Kim GK: Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? J Clin Aesthet Dermatol 2011, 4:17-26.
• [91]Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA: Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 2001, 92:354-60.
• [92]Sjoblom T, Shimizu A, O’Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001, 61:5778-83.
• [93]Llombart B, Sanmartin O, Lopez-Guerrero JA, Monteagudo C, Serra C, Requena C, Poveda A, Vistos JL, Almenar S, Llombart-Bosch A, Guillen C: Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Histopathology 2009, 54:860-72.
• [94]Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002, 100:623-6.
• [95]Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-91.
• [96]Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-55.
• [97]Martin V, Mazzucchelli L, Frattini M: An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009, 62:314-24.